指南与共识食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病消化内镜

AGA临床实践更新:胃食管反流病评估与管理的个体化方法专家综述

AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2022-02-02

该专家综述指出多达半数疑似胃食管反流病(GERD)患者无法从抑酸治疗中获益,并提出个体化诊疗路径。全文以14条最佳实践建议的形式,涵盖共享决策、患者教育、PPI试验与降阶梯、难治性症状的客观监测、内镜评估、辅助药物个体化、神经调节与行为治疗,以及侵入性抗反流手术的适应证选择。

要点

  • 对疑似GERD症状,应在共享决策模式下制定检查、治疗选择与长期管理计划。
  • 无报警症状的烧心、反流或非心源性胸痛,可给予4至8周单剂量PPI试验,按应答调整剂量或降阶梯。
  • PPI试验应答不佳或有报警症状时,应行内镜及停药后延长无线pH监测以确认并分型GERD。

核心结论

  • 多达半数疑似GERD患者无法从抑酸治疗中获益,需采用个体化诊断与治疗路径。
  • 本实践更新以专家意见为基础提出14条最佳实践建议,未对证据质量或推荐强度进行正式评级。

研究设计与样本

  • 本文为AGA临床实践更新专家综述,基于现有文献的专家回顾并结合广泛讨论与专家意见形成实践建议。
  • 本文未对证据质量或推荐强度进行正式评级,并非该临床实践更新的目的。

主要发现

  • 多达半数疑似GERD患者无法从抑酸治疗中获益。
  • 无报警症状的烧心、反流和/或非心源性胸痛患者,可给予4至8周单剂量PPI试验。
  • PPI试验应答不足时,剂量可增至每日两次或换用更有效的抑酸药物每日一次;应答充分时,PPI应减至最低有效剂量。
  • 对未证实GERD而继续PPI治疗者,应在起始后12个月内评估适宜性与剂量,并可行停药后延长无线反流监测。
  • GERD症状的内镜完整评估包括 erosive esophagitis(按洛杉矶分级)、膈肌裂孔(Hill flap valve分级)、轴向裂孔疝长度及Barrett食管(按布拉格分级并活检)。

关键数值与推荐

  • 最佳实践建议1:临床医生应在共享决策模式下与患者制定针对疑似GERD症状的检查、治疗选择(解释潜在风险与获益)及长期管理(包括可能的降阶梯)的照护计划。
  • 最佳实践建议2:临床医生应向反流症状患者提供关于GERD机制、体重管理、生活方式与饮食行为、放松策略及脑-肠轴关系的标准化教育材料。
  • 最佳实践建议3:临床医生应强调质子泵抑制剂(PPI)治疗GERD的安全性。
  • 最佳实践建议4:无报警症状的烧心、反流和/或非心源性胸痛患者,应给予4至8周单剂量PPI试验;应答不足可增至每日两次或换用更有效抑酸药每日一次;应答充分则PPI减至最低有效剂量。
  • 最佳实践建议5:未证实GERD而继续PPI者,应在起始后12个月内评估适宜性与剂量,并可行停药后延长无线反流监测以确立长期PPI适宜性。

临床怎么用

  • 临床医生应在共享决策模式下制定GERD症状检查、治疗选择与长期管理计划。
  • 临床医生应向反流症状患者提供GERD机制、体重管理、生活方式与饮食行为、放松策略及脑-肠轴关系的标准化教育材料。
  • 临床医生应强调PPI治疗GERD的安全性。
  • 无报警症状的烧心、反流和/或非心源性胸痛患者可接受4至8周单剂量PPI试验,并按应答调整剂量或降阶梯。
  • 对PPI试验应答不足或有报警症状者,应行内镜及停药后延长无线pH监测以确认并分型GERD或排除GERD。

局限性

  • 本文未对证据质量或推荐强度进行正式评级,建议基于专家意见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: As many as one-half of all patients with suspected gastroesophageal reflux disease (GERD) do not derive benefit from acid suppression. This review outlines a personalized diagnostic and therapeutic approach to GERD symptoms. METHODS: The Best Practice Advice statements presented here were developed from expert review of existing literature combined with extensive discussion and expert opinion to provide practical advice. Formal rating of the quality of evidence or strength of recommendations was not the intent of this clinical practice update. BEST PRACTICE ADVICE 1: Clinicians should develop a care plan for investigation of symptoms suggestive of GERD, selection of therapy (with explanation of potential risks and benefits), and long-term management, including possible de-escalation, in a shared-decision making model with the patient. BEST PRACTICE ADVICE 2: Clinicians should provide standardized educational material on GERD mechanisms, weight management, lifestyle and dietary behaviors, relaxation strategies, and awareness about the brain-gut axis relationship to patients with reflux symptoms. BEST PRACTICE ADVICE 3: Clinicians should emphasize safety of proton pump inhibitors (PPIs) for the treatment of GERD. BEST PRACTICE ADVICE 4: Clinicians should provide patients presenting with troublesome heartburn, regurgitation, and/or non-cardiac chest pain without alarm symptoms a 4- to 8-week trial of single-dose PPI therapy. With inadequate response, dosing can be increased to twice a day or switched to a more effective acid suppressive agent once a day. When there is adequate response, PPI should be tapered to the lowest effective dose. BEST PRACTICE ADVICE 5: If PPI therapy is continued in a patient with unproven GERD, clinicians should evaluate the appropriateness and dosing within 12 months after initiation, and offer endoscopy with prolonged wireless reflux monitoring off PPI therapy to establish appropriateness of long-term PPI therapy. BEST PRACTICE ADVICE 6: If troublesome heartburn, regurgitation, and/or non-cardiac chest pain do not respond adequately to a PPI trial or when alarm symptoms exist, clinicians should investigate with endoscopy and, in the absence of erosive reflux disease (Los Angeles B or greater) or long-segment (≥3 cm) Barrett's esophagus, perform prolonged wireless pH monitoring off medication (96-hour preferred if available) to confirm and phenotype GERD or to rule out GERD. BEST PRACTICE ADVICE 7: Complete endoscopic evaluation of GERD symptoms includes inspection for erosive esophagitis (graded according to the Los Angeles classification when present), diaphragmatic hiatus (Hill grade of flap valve), axial hiatus hernia length, and inspection for Barrett's esophagus (graded according to the Prague classification and biopsied when present). BEST PRACTICE ADVICE 8: Clinicians should perform upfront objective reflux testing off medication (rather than an empiric PPI trial) in patients with isolated extra-esophageal symptoms and suspicion for reflux etiology. BEST PRACTICE ADVICE 9: In symptomatic patients with proven GERD, clinicians should consider ambulatory 24-hour pH-impedance monitoring on PPI as an option to determine the mechanism of persisting esophageal symptoms despite therapy (if adequate expertise exists for interpretation). BEST PRACTICE ADVICE 10: Clinicians should personalize adjunctive pharmacotherapy to the GERD phenotype, in contrast to empiric use of these agents. Adjunctive agents include alginate antacids for breakthrough symptoms, nighttime H2 receptor antagonists for nocturnal symptoms, baclofen for regurgitation or belch predominant symptoms, and prokinetics for coexistent gastroparesis. BEST PRACTICE ADVICE 11: Clinicians should provide pharmacologic neuromodulation, and/or referral to a behavioral therapist for hypnotherapy, cognitive behavioral therapy, diaphragmatic breathing, and relaxation strategies in patients with functional heartburn or reflux disease associated with esophageal hypervigilance reflux hypersensitivity and/or behavioral disorders. BEST PRACTICE ADVICE 12: In patients with proven GERD, laparoscopic fundoplication and magnetic sphincter augmentation are effective surgical options, and transoral incisionless fundoplication is an effective endoscopic option in carefully selected patients. BEST PRACTICE ADVICE 13: In patients with proven GERD, Roux-en-Y gastric bypass is an effective primary anti-reflux intervention in obese patients, and a salvage option in non-obese patients, whereas sleeve gastrectomy has potential to worsen GERD. BEST PRACTICE ADVICE 14: Candidacy for invasive anti-reflux procedures includes confirmatory evidence of pathologic GERD, exclusion of achalasia, and assessment of esophageal peristaltic function.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Yadlapati R, Gyawali CP, Pandolfino JE, et al. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022. PMID: 35123084. doi:10.1016/j.cgh.2022.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。